Author Archives: admin


Puppies receive stem cell treatment developed to help children with spina bifida – Sacramento Bee


Sacramento Bee
Puppies receive stem cell treatment developed to help children with spina bifida
Sacramento Bee
A procedure combining surgery with stem cell treatment has aided two bulldog puppies with spina bifida and a team of UC Davis researchers hopes to test the therapy in human clinical trials. The puppies were treated with a therapy developed at UC Davis ...

Read more from the original source:
Puppies receive stem cell treatment developed to help children with spina bifida - Sacramento Bee

Stem Cells Being Tested to Treat Type 1 Diabetes – Newsmax

Scientists are conducting a study that would use human stem cells to repopulate insulin-producing cells destroyed by Type 1 diabetes. The cells would be grown in the lab and transplanted to diabetes patients. The process looks very promising, and the transplanted cells would begin producing insulin immediately and could revolutionize diabetes treatment.

Microscopic groups of cells, called islets, are responsible for producing insulin in the pancreas. But Type 1 diabetes tricks the immune system into killing these cells, causing a lifelong dependency on insulin shots. Without insulin, cells could not obtain energy from sugars (glucose) and would starve leading to loss of vision, heart conditions, and even death.

A lifelong dependency on shots, that is, unless islets could be restored in the pancreas. Enter researchers at the University of Pittsburgh Swanson School of Engineering who are investigating the use of stem cells to engineer pancreatic islets in the lab. Step 1: meeting the oxygen demands of the pancreatic cells. Since these islets have a very high oxygen demand, researchers began looking for new techniques to speed up the oxygen possibilities after tests began to show this would ultimately improve cell life and transplantation outcome.

Ipsita Banerjee, associate professor of chemical engineering at the University of Pittsburgh and lead investigator of the study, said, "Through collaborative efforts, we have developed a method of implanting blood vessel fragments into the islets. By vascularizing the islets before they are transplanted to the body, they are more likely to survive and can begin regulating blood glucose more quickly."

Blood vessels carry out the oxygenation process for the cells, and once researchers overcame this huge obstacle, they set their sights on converting stem cells into Type 1 diabetes-resistant supercells. The process in underway, and Banerjee and colleagues hope to have a working process in the near future.

2017 NewsmaxHealth. All rights reserved.

Read more here:
Stem Cells Being Tested to Treat Type 1 Diabetes - Newsmax

Healing by regeneration – Jamaica Observer

ONE year ago Sandrene Brown could not climb a flight of stairs without holding on to the rails for support. The simple act, which is routine for so many people, was just too painful.

However, she is now pain-free and can run up and down stairways to her liking.

In fact, like Brown, two other patients at St Ann's Bay Hospital might have similar stories to share after today. The two will be undergoing platelet-rich plasma procedures, one for shoulder impingement and the other for arthritis in both knees.

Orthopaedic surgeon at the hospital Dr Derrick McDowell told the Jamaica Observer that since he started doing stem cell surgeries early last year which, along with platelet-rich plasma procedures, forms part of the facility's thrust towards regenerative surgical procedures nearly 70 people have so far benefited.

I am, more or less, the only person to do them locally and in the Caribbean, Dr McDowell said of stem cell therapy.

[This] is where we do procedures to help people to regenerate to get back to the original quality and function.

On Friday I will be doing what's called platelet-rich plasma procedure, which is separating it from the blood, but with the stem cells we get it from the bone marrow. So we get the stem cells from the bone marrow and put it to the [affected] area under image guidance and, of course, we ensure that it does what it's supposed to do, he said.

The orthopaedic surgeon explained that since the bone transplant programme started at the hospital in 2013, adjunct to that was patients' healing, which led to regenerative surgical procedures.

Heal by regeneration, so stem cell surgery was the next logical step in that progress, he said. So what I started to do is what's called autologous somatic stem cells treatment so there are no ethical issues involved.

Autologous means the cells are obtained from the same individual, so the donor and recipient are the same.

So you basically go to the body reserves the body has stem cells and you isolate the stem cells and then you instil the stem cells under image guidance, such as ultrasound or X-rays, Dr McDowell said.

The doctor told the Observer that stem cell therapy has been working well for people who have muscular problems as well as ligament, joint and nerve issues.

But how exactly does the procedure help these people?

He explained that if a wound was to heal by regeneration, there would be no scar.

Cuts on your body with a scar were healed by scar formation So what you have there is skin, and that skin covers the area, but it doesn't have any sweat glands, no hair follicles; it doesn't look like normal skin, he explained.

[With regeneration] basically what we are doing is forcing the tissue to heal by regrowing its own native tissue, he said.

Dr McDowell said further that if a patient has arthritis, where the cartilage is damaged, we basically do a procedure to make the cartilage reform.

If you have nerves which have been damaged by trauma by chronic compression, like carpal tunnel syndrome and so on, we get the nerves to heal by growing back new nerves, he continued. And people who need joint replacement, for example, we can delay the operative surgery of doing joint replacement by giving them stem cells.

For Brown, though she told the Observer she was hesitant to do the procedure when she was told she had early stage arthritis, she feels much better having done it.

Honestly, I can climb stairs, run up stairs, run down stairs without any problem now, Brown said yesterday. I think it has done what it should've done; there is no relapse or anything like that.

Having branched off into regenerative procedures through stem cell surgery, Dr McDowell said what this does for the bone transplant programme at St Ann's Bay Hospital is improve healing rates.

So what's next?

Who knows? The sky is the limit, Dr McDowell responded.

The orthopaedic surgeon told the Observer that the stem cell therapy at the regional hospital is being done through a partnership with Surgix Jamaica Ltd, which is responsible for the preparation of the stem cells.

Surgix CEO Winfield Boban said yesterday that his company is trying to make treatment opportunities accessible to all Jamaicans.

Surgix provides the equipment and know-how in providing stem cell therapy across Jamaica and the Caribbean, but mostly Jamaica. Along with Dr McDowell, we provide equipment and the specialised staff and things like that, and all he does is now apply the stem cells, Boban said.

What we have done is to be able to make stem cell therapy as affordable and as accessible to the Jamaican community as possible, utilising innovators and pioneers such as Dr McDowell; we are getting the message across, Boban added.

The CEO pointed out that athletes such as Asafa Powell and Yohan Blake, if they wanted to do stem cell surgery, would have to travel to Germany, the United Kingdom, Switzerland, or the United States, but his company has brought the equipment to the shores of Jamaica.

We have been able to bring that science here and make it available not only for premier athletes to access it, but upcoming athletes too so we trying to level the playing field and make it accessible to the wider Jamaican community, he said.

Read more:
Healing by regeneration - Jamaica Observer

How a UCSF study could change the lives of babies in the womb and maybe help California’s stem cell program in … – San Francisco Business Times

How a UCSF study could change the lives of babies in the womb and maybe help California's stem cell program in ...
San Francisco Business Times
The world's first in-utero blood stem cell transplant, soon to be performed at the University of California, San Francisco, could point the way toward pre-birth cures for a range of blood diseases, such as sickle cell disease. It's also the sort of ...

and more »

Originally posted here:
How a UCSF study could change the lives of babies in the womb and maybe help California's stem cell program in ... - San Francisco Business Times

Global Parkinson’s Disease Drugs Market Outlook 2022 – Markets Insider

NEW YORK, Aug. 23, 2017 /PRNewswire/ -- Parkinson's disease belongs to the group of conditions called motor system disorders. This disease is a result of loss of dopamine producing neurons in the brain. The four primary symptoms of Parkinson's disease are tremors, rigidity, slowness of movement and postural instability. Although, there is no cure for Parkinson's disease, several medications are used to suppress the symptoms of the disease.

Read the full report: http://www.reportlinker.com/p05075843/Global-Parkinsons-Disease-Drugs-Market-Outlook.html

As per RNCOS report "Global Parkinson's Disease Drugs Market Outlook 2022", the global Parkinson's disease drugs market is anticipated to witness a moderate growth during 2016-2022. This report provides a detailed analysis of the current and future market scenario of the global Parkinson's disease drugs market. The report provides insight about the major drivers, such as increasing awareness about Parkinson's disease and its treatment options, research grants and funds, for the global Parkinson's disease drugs market.

Furthermore, few challenges, such as patent expiry and high cost of treatment, which are hindering the growth of the global Parkinson's disease drugs market have also been mentioned in the report. In addition, the report also highlights various opportunities available for growth of the global Parkinson's disease drugs market.

The global Parkinson's disease drugs market has been segmented on the basis of type of therapy into levodopa therapy, dopamine therapy, MAO-B inhibitor therapy, COMT inhibitor therapy, and other types of therapies. Among all the types, levodopa therapy is the first and most potent treatment for the Parkinson's disease. The benefits of the medication are witnessed soon after administration.

Apart from these types of therapies, various pharmaceutical and biotech companies are also developing stem cell therapy for the treatment of Parkinson's disease. Stem cell therapy is an evolving field which makes use of stem cells to treat or prevent a disease or condition, such as Parkinson's disease. Even a minimal success from this procedure can mean significant improvement in quality of life for patients.

Numerous companies, such as SanBio Inc and International Stem Cell Corp, are carrying out clinical trials for stem cell therapies for the treatment of Parkinson's disease. Hence, stem cell therapy presents great opportunities for the growth of global Parkinson's disease drugs market in the coming years.

Based on geography, the report divides the market into North America, Europe, and Asia-Pacific. In 2016, North America accounted for the largest share in the global Parkinson's disease drugs market. Moreover, the report also highlights various mergers and acquisitions taking place in the global Parkinson's disease drugs industry. The drugs pipeline of Parkinson's disease has also been mentioned in the report.

Read the full report: http://www.reportlinker.com/p05075843/Global-Parkinsons-Disease-Drugs-Market-Outlook.html

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com __________________________ Contact Clare: rel="nofollow">clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/global-parkinsons-disease-drugs-market-outlook-2022-300508683.html

SOURCE Reportlinker

Read more here:
Global Parkinson's Disease Drugs Market Outlook 2022 - Markets Insider

Test reveals possible treatments for disorders involving MeCP2 – Baylor College of Medicine News (press release)

The first step consisted of genetically modifying a laboratory cell line in which the researchers could monitor the levels of fluorescent MeCP2 as they inhibited molecules that might be involved in its regulation. First author Dr. Laura Lombardi, a postdoctoral researcher in the Zoghbi lab at the Howard Hughes Medical Institute, developed this cell line and then used it to systematically inhibit one by one the nearly 900 kinase and phosphatase genes whose activity could be potentially inhibited with drugs.

We wanted to determine which ones of those hundreds of genes would reduce the level of MeCP2 when inhibited, Lombardi said. If we found one whose inhibition would result in a reduction of MeCP2 levels, then we would look for a drug that we could use.

The researchers identified four genes than when inhibited lowered MeCP2 level. Then, Lombardi and her colleagues moved on to the next step, testing how reduction of one or more of these genes would affect MeCP2 levels in mice. They showed that mice lacking the gene for the kinase HIPK2 or having reduced phosphatase PP2A had decreased levels of MeCP2 in the brain.

These results gave us the proof of principle that it is possible to go from screening in a cell line to find something that would work in the brain, Lombardi said.

Most interestingly, treating animal models of MECP2 duplication syndrome with drugs that inhibit phosphatase PP2A was sufficient to partially rescue some of the motor abnormalities in the mouse model of the disease.

This strategy would allow us to find more regulators of MeCP2, Zoghbi said. We cannot rely on just one. If we have several to choose from, we can select the best and safest ones to move to the clinic.

Beyond MeCP2, there are many other genes that cause a medical condition because they are either duplicated or decreased. The strategy Zoghbi and her colleagues used here also can be applied to these other conditions to try to restore the normal levels of the affected proteins and possibly reduce or eliminate the symptoms.

Other contributors to this work include Manar Zaghlula, Yehezkel Sztainberg, Steven A. Baker, Tiemo J. Klisch, Amy A. Tang and Eric J. Huang.

This project was funded by the National Institutes of Health (5R01NS057819), the Rett Syndrome Research Trust and 401K Project from MECP2 duplication syndrome families, and the Howard Hughes Medical Institute. This work also was made possible by the following Baylor College of Medicine core facilities: Cell-Based Assay Screening Service (NIH, P30 CA125123), Cytometry and Cell Sorting Core (National Institute of Allergy and Infectious Diseases, P30AI036211; National Cancer Institute P30CA125123; and National Center for Research Resources, S10RR024574), Pathway Discovery Proteomics Core, the DNA Sequencing and Gene Vector Core (Diabetes and Endocrinology Research Center, DK079638), and the mouse behavioral core of the Intellectual and Developmental Disabilities Research Center (NIH, U54 HD083092 from the National Institute of Child Health and Human Development).

The full study can be found inScience Translational Medicine.

Read more:
Test reveals possible treatments for disorders involving MeCP2 - Baylor College of Medicine News (press release)

SQZ Biotech Expands Leadership Team, Appoints Shefali Agarwal, MD, MPH, as Chief Medical Officer – Markets Insider

WATERTOWN, Mass., Aug. 23, 2017 /PRNewswire/ --SQZ Biotech (SQZ), a preclinical stage biotechnology company developing cell therapies based on its proprietary CellSqueeze technology, announced today the appointment of Shefali Agarwal, MD, MPH, as Chief Medical Officer. As the newest member of the SQZ executive team, Dr. Agarwal, a trained medical oncologist, will lead the Company's clinical and translational development, regulatory planning and execution.

"We are thrilled to have Shefali join the SQZ team. Her deep clinical experience, strategic expertise and track record are exactly what we need to bring our cell therapy concepts to the clinic," said Armon Sharei, PhD, Chief Executive Officer. "With her hands-on oncology background and personal drive to improve patient outcomes, Shefali clearly shares our deep-seated commitment to impact patient lives through a new generation of cell therapies."

Dr. Agarwal served most recently as Senior Vice President, Head of Clinical Development at Curis Inc, where she built the development team and provided leadership across all clinical and medical areas. Concurrently, she continued her previous role at Tesaro as Senior Medical Director, Clinical Lead on Zejula, responsible for designing and overseeing clinical studies and regulatory interactions, as well as serving as clinical lead for NDA submission and for the drug's launch team. Prior to joining Tesaro, Dr. Agarwal was Medical Director at Covidien and then at AVEO Oncology. She began her career in industry at Pfizer, responsible for patient safety and medical oversight of global clinical programs, during which tenure she participated in a successful NDA submission of Torisel and supported clinical studies for the NDA submission of Bosufil.

Dr. Agarwal received her Medical Degree from MRMC Medical School in India, holds a Master's of Science in Business from Merrick School of Business, as well as a Master's in Public Health from Johns Hopkins University. Additionally, she trained at Hopkins, where Dr. Agarwal led clinical research in the OBGYN and anesthesiology department and was an investigator on multiple industry trials, hospital-sponsored INDs, and NIH studies.

"I am greatly inspired by the team at SQZ. Innovating novel, cell-based treatments for patients, SQZ has the potential to broadly transform approaches to personalized medicine and immunotherapy, as well as cell therapy, across diverse disease indications," Dr. Agarwal stated. "The Company has tremendous momentum progressing in the early stages of R&D, and we look forward to further advancing our programs to IND filing and entry into the clinic."

About SQZ Biotech SQZ Biotechnologies is a Massachusetts based, privately held company developing cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ's unique cell engineering capabilities are being used to develop a new generation of cell therapies to address a wide range of clinical challenges. For more information please visit http://www.sqzbiotech.com.

SQZ Contact: Rebecca Cohen Manager, Corporate Relations & Administration617-758-8672 ext. 728 class="prnews_a" rel="nofollow">rebecca.cohen@sqzbiotech.com

Media Contact: Justin Jackson Burns McClellan 212-213-0006 ext. 327 class="prnews_a" rel="nofollow"> jjackson@burnsmc.com

View original content:http://www.prnewswire.com/news-releases/sqz-biotech-expands-leadership-team-appoints-shefali-agarwal-md-mph-as-chief-medical-officer-300508021.html

SOURCE SQZ Biotechnologies

See more here:
SQZ Biotech Expands Leadership Team, Appoints Shefali Agarwal, MD, MPH, as Chief Medical Officer - Markets Insider

About Medicine: Teaching teens and tweens about online risks – Ravalli Republic

Todays tweens and teens are connected to one another, and to the world, via digital technology more than any previous generation. Recent Studies show that 95 percent of teens ages 12-17 are online, 78 percent own cell phones, one in four teens has a tablet computer and nine out of 10 teens has access to a computer at home. While todays adolescents may be more digitally savvy than their parents, their lack of maturity and life experiences can quickly get them into trouble. With back to school here, it is especially important to visit both the benefits and risks of social media and internet use in our children.

There are certainly many benefits to social media and internet today and especially for our children. They can stay connected with friends and family, make new friends, share pictures and exchange ideas. They use social media sites for networking for school projects and studying, they can express themselves through blogs, community engagement for charity and volunteering, and improving tolerance by exposing them to diverse ideas and people. It also helps with their health and the mobile technologies have already improved this by increasing medication adherence, better disease understanding and fewer missed appointments.

Despite all of the benefits, there are obviously clear risks. Although it may increase their communication overall, there is a worry that they are spending more time online then in face to face conversation. This may change the ways our children interact and their ability to converse in person.

Cyberbullying is a really big issue and is the most common online risk for all teens. It is deliberately using digital media to communicate false, embarrassing, or hostile information about another person. It can have profound consequences such as depression, anxiety, severe isolation and tragically, suicide.

The disbursement of too much information has lasting consequences as well. Sexting is a risky problem with reports that 20 percent of teens have sent or posted inappropriate photos or videos of themselves. This can have not only personal consequences if the recipients over-share but legal consequences depending on participants ages. In the case of social media sites what goes online, stays online and can affect future college and job acceptance.

There is a new diagnosis that is being researched called Facebook depression that is the development of symptoms of depression after spending a long time on social media sites. The thoughts are that teens compare their lives to others, have less in person interaction and they go online to escape the real world.

Finally, time spent on social media affects sleep. Social media use is linked with less hours of sleep in teens as well as having a TV in the bedroom and having a cell phone. One thought is that the light from screens affects circadian rhythms making it difficult to fall asleep after use.

We know that social media does have positive influences on our children and technology is certainly not going away so we have to have proactive ways to manage the risk in our children. Parents should learn about these technologies first hand. There is simply no better way than to have a profile yourself. It will also enable you to friend your kids and monitor them online. Also having an open discussion with kids and let them know that their online presence is something that you want and need to know about. Keep computers in a public part of your home so you can monitor what they are doing and how much time they are spending there. Emphasize that everything sent over the internet or cell phone can be shared with the entire world, so it is important they use good judgement. Consequences can reach into adulthood and in some cases are legal ones. Have your kids show you their privacy settings and check in regularly to make sure they havent changed. Set limits for internet and cell phone use and learn the signs of trouble: skipping activities, meals and homework for social media; weight loss or gain; a drop in grades. Check chat logs, emails, files and social networking profiles for inappropriate content, friends, messages and images periodically. It is extremely important that you are transparent with your children so they know what you will be doing. Be sure to stress the importance of not using their phone when driving or doing other activities that require their full attention. Have a discussion with children of appropriate age about sexting. Make sure they understand that it is unsafe and can have legal consequences in some instances. And finally try to limit screen time one to two hours before bedtime.

Technology is here to stay and if used appropriately can be an adjunctive to a rich and meaningful life. If we teach our kids responsible social media and internet use early, it can contribute to a richer and more meaningful connection with people and the world. There is plenty of more in depth resources for this online especially through the American Academy of Pediatrics website and I encourage all parents to be proactive in their engagement with their children. I also encourage all parents to discuss this with their family physician for further information.

This weeks health column is collaboration between Ravalli Family Medicine and Marcus Daly Memorial Hospital. Questions and or comments regarding this weeks health column please contact Allisun Jensen, PA-C at Ravalli Family Medicine, 411 West Main Street, Hamilton, MT 59840. Working together to build a healthier community!

Excerpt from:
About Medicine: Teaching teens and tweens about online risks - Ravalli Republic

Washington University School of Medicine; Asterias Biotherapeutics Opens Additional Clinical Site for AST-OPC1 … – STL.News

FREMONT, Calif., Aug. 23, 2017 (STL.NEWS) Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced that Washington University School of Medicine in St. Louis, MO, has been added as a clinical site in the companys ongoing SCiStar Phase 1/2a clinical trial of AST-OPC1, a stem-cell derived investigational therapy, in patients with severe cervical spinal cord injury (SCI). There are now nine clinical sites enrolling patients in the study.

Washington University and its partner Barnes-Jewish Hospital have one of the largest clinical spine care practices in the United States. W. Zachary Ray, MD, Associate Professor of Neurological and Orthopedic Surgery at Washington University School of Medicine, will be the sites principal investigator. Patients enrolled in the trial will receive the AST-OPC1 treatment during surgery at Barnes-Jewish.

Given the studys encouraging early results, we look forward to evaluating whether AST-OPC1 can advance treatment options for patients with severe cervical spinal cord injuries. This investigational therapy is an important contribution to our comprehensive program to treat spinal cord injuries here at Washington University and Barnes-Jewish, said Dr. Ray.

Barnes-Jewish Hospitals Trauma Center was the first in Missouri to receive the American College of Surgeons (ACS) Level I verification, which is the highest national recognition possible from ACS.

Washington University School of Medicine is a great addition to our current AST-OPC1 SCiStar study. We hope Washington University School of Medicine will also participate in a future randomized controlled trial of AST-OPC1, stated Dr. Edward Wirth III, Chief Medical Officer of Asterias Biotherapeutics.

About the SCiStar Trial

The SCiStar trial is an open-label, single-arm trial testing three sequential escalating doses of AST-OPC1 administered at up to 20 million AST-OPC1 cells in as many as 35 patients with subacute motor complete (AIS-A or AIS-B) cervical (C-4 to C-7) SCI. These individuals have essentially lost all movement below their injury site and experience severe paralysis of the upper and lower limbs. AIS-A patients have lost all motor and sensory function below their injury site, while AIS-B patients have lost all motor function but may have retained some minimal sensory function below their injury site. AST-OPC1 is being administered 21 to 42 days post-injury. Patients will be followed by neurological exams and imaging procedures to assess the safety and activity of the product.

The study is being conducted at nine centers in the U.S. Clinical sites involved in the study include the Medical College of Wisconsin in Milwaukee, Shepherd Medical Center in Atlanta, University of Southern California (USC) jointly with Rancho Los Amigos National Rehabilitation Center in Los Angeles, Indiana University, Rush University Medical Center in Chicago, Santa Clara Valley Medical Center in San Jose jointly with Stanford University, Thomas Jefferson University Hospital in partnership with Magee Rehabilitation Hospital in Philadelphia, UC San Diego Health in San Diego, California, and Washington University School of Medicine in partnership with Barnes-Jewish Hospital in St. Louis, MO.

Asterias has received a Strategic Partnerships Award grant from the California Institute for Regenerative Medicine, which provides $14.3 million of non-dilutive funding for the Phase 1/2a clinical trial and other product development activities for AST-OPC1.

Additional information on the Phase 1/2a trial, including trial sites, can be found at http://www.clinicaltrials.gov, using Identifier NCT02302157, and at the SCiStar Study Website (www.SCiStar-study.com).

About AST-OPC1

AST-OPC1, an oligodendrocyte progenitor population derived from human embryonic stem cells originally isolated in 1998, has been shown in animals and in vitro to have three potentially reparative functions that address the complex pathologies observed at the injury site of a spinal cord injury. These activities of AST-OPC1 include production of neurotrophic factors, stimulation of vascularization, and induction of remyelination of denuded axons, all of which are critical for survival, regrowth and conduction of nerve impulses through axons at the injury site. In preclinical animal testing, AST-OPC1 administration led to remyelination of axons, improved hindlimb and forelimb locomotor function, dramatic reductions in injury-related cavitation and significant preservation of myelinated axons traversing the injury site.

In a previous Phase 1 clinical trial, five patients with neurologically complete, thoracic spinal cord injury were administered two million AST-OPC1 cells at the spinal cord injury site 7-14 days post-injury. Based on the results of this study, Asterias received clearance from FDA to progress testing of AST-OPC1 to patients with cervical spine injuries in the current SCiStar study, which represents the first targeted population for registration trials. Asterias has completed enrollment in the first four cohorts of this study. Results to date have continued to support the safety of AST-OPC1. Additionally, Asterias has recently reported results suggesting reduced cavitation and improved motor function in patients administered AST-OPC1 in the SCiStar trial.

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc. is a biotechnology company pioneering the field of regenerative medicine. The companys proprietary cell therapy programs are based on its pluripotent stem cell and immunotherapy platform technologies. Asterias is presently focused on advancing three clinical-stage programs which have the potential to address areas of very high unmet medical need in the fields of neurology and oncology. AST-OPC1 (oligodendrocyte progenitor cells) is currently in a Phase 1/2a dose escalation clinical trial in spinal cord injury. AST-VAC1 (antigen-presenting autologous dendritic cells) is undergoing continuing development by Asterias based on promising efficacy and safety data from a Phase 2 study in Acute Myeloid Leukemia (AML), with current efforts focused on streamlining and modernizing the manufacturing process. AST-VAC2 (antigen-presenting allogeneic dendritic cells) represents a second generation, allogeneic cancer immunotherapy. The companys research partner, Cancer Research UK, plans to begin a Phase 1/2a clinical trial of AST-VAC2 in non-small cell lung cancer in 2017. Additional information about Asterias can be found at http://www.asteriasbiotherapeutics.com.

FORWARD-LOOKING STATEMENTS

Statements pertaining to future financial and/or operating and/or clinical research results, future growth in research, technology, clinical development, and potential opportunities for Asterias, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the businesses of Asterias, particularly those mentioned in the cautionary statements found in Asterias filings with the Securities and Exchange Commission. Asterias disclaims any intent or obligation to update these forward-looking statements.

source; Asterias Biotherapeutics , published on STL.NEWS by St Louis Media, LLC

Visit link:
Washington University School of Medicine; Asterias Biotherapeutics Opens Additional Clinical Site for AST-OPC1 ... - STL.News

Stem Cell Study for Dogs – MyWabashValley

Terre Haute, IN - Maggie Mae and her owner Robert Howrey come from Paris, Illinois for a check-up at the Wabash Valley Animal Hospital in Terre Haute. She doesn't act like it, but Maggie Mae is a senior citizen and she has problems with her joints.

"Arthritis is a common condition in older dogs and we like to help them out," said Dr. Andrew Pickering, veterinarian.

A California company called "Animal Cell Therapies" has enlisted veterinarians all across the country to participate in a study of using stem cells for dogs with arthritis. Some of the canines in the study receive an injection of stem cells, others get just a saline solution.

Local vet, Doctor Andrew Pickering doesn't know which injections Maggie Mae is getting, but she no longer limps, and he's encouraged by the results.

"We're hoping this particular type of treatment will cure the condition for a long period of time so we don't have to keep giving the dog medication all the time," said Pickering.

Howrey says it's almost like having a new dog. "It's been about six weeks, so now she's back doing normal activities, she runs, she chases squirrels "

The research will continue for several more months. And the local clinic is still looking for owners who would like to get their pets involved. Study participation is free for dogs that qualify. Plus, even the animals that receive the saline injections will be able to get the stem cell treatment once the study is complete.

Click here to connect with the study web page

Click here to connect with the Wabash Valley Animal Hospital

View post:
Stem Cell Study for Dogs - MyWabashValley